4basecare launches AI-based clinical interpretation platform for oncologistsJanuary 10, 2021 0 By FM
The precision oncology start-up company 4basecare has joined hands with the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) – Tata Memorial Centre for a new artificial intelligence-driven clinical interpretation platform, ClinOme.
The collaboration aims at developing an indigenous platform to generate data insights and simplified reports to guide oncologists to offer personalised treatment options for treating cancer patients.
“While genomics data analysis is a challenge, evidence based therapeutic inference is altogether another challenge. ClinOme addresses both of the challenges using a combination of genomics best practices and artificial intelligence powered evidence based therapeutic inference”, says Dr Pratik Chanarani is Scientific Officer, ACTREC-Tata Memorial Hospital.
ClinOme is a graphical user interface (GUI) based automated tool developed by senior scientists & clinicians from ACTREC & Tata Memorial Hospital. The platform automates quality check, primary, secondary and tertiary analysis of raw next generation sequencing (NGS) data followed by comprehensive clinical report generation that can be easily comprehended by the clinicians for analysis.
ClinOme provides easy to interpret categorisation of genomic alterations along with approved and experimental therapeutic options for each responsive and resistant genotype-drug combination, says the company.
The output of ClinOme analysis consists of a report with detailed patient centric genotype to help design informed therapeutic option. The report also consists of links to the specific ongoing clinical trials, gene-wise coverage statistics and allelic frequency of the genomic variants.
“Patient-to-patient variation in treatment response as observed routinely in clinics, suggests that personal targeting of cancer, based on tumour molecular proﬁles, is necessary.” says Dr. Amit Dutt, Principal Investigator, Scientist, ACTREC -Tata Memorial Hospital.
“Genomic testing has become important in the management of cancer. NGS is emerging as a comprehensive solution for genomic testing. It a complex process where the bioinformatics pipeline is a very important component. ClinOme provides a very useful indigenous solution in this area”, says Dr. Kumar Prabhash, Professor and Medical Oncologist, Tata Memorial Hospital.